The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency’s drug program, the latest in a string of leadership changes at the agency. FDA Commissioner ...

Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty ...

Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to strengthen FDA’s drug review and innovation efforts.

The FDA is calling on produce growers, buyers, sellers and regulators to form a stakeholder collaboration that includes ...

The federal agency introduced Elsa last month, boasting about the AI tool's ability to increase efficiency at the FDA.

To be eligible for the FDA’s new Commissioner’s National Priority Voucher program, a drug must meet certain national health interests. Qualifying medicines could be reviewed in one to two ...

FDA's long-standing accelerated approval program generally issues decisions in six months for drugs that treat life-threatening diseases. Regular drug reviews take about 10 months.

FDA's long-standing accelerated approval program generally issues decisions in six months for drugs that treat life-threatening diseases. Regular drug reviews take about 10 months.